KW-3357 + Plasma-derived antithrombin
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Disseminated Intravascular Coagulation (DIC)
Conditions
Disseminated Intravascular Coagulation (DIC)
Trial Timeline
Jun 1, 2011 → May 1, 2013
NCT ID
NCT01384903About KW-3357 + Plasma-derived antithrombin
KW-3357 + Plasma-derived antithrombin is a phase 3 stage product being developed by Kyowa Kirin for Disseminated Intravascular Coagulation (DIC). The current trial status is completed. This product is registered under clinical trial identifier NCT01384903. Target conditions include Disseminated Intravascular Coagulation (DIC).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01384903 | Phase 3 | Completed |
Competing Products
5 competing products in Disseminated Intravascular Coagulation (DIC)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KW-3357 | Kyowa Kirin | Phase 3 | 77 |
| KW-3357 | Kyowa Kirin | Phase 3 | 77 |
| Single high dose of liposomal amphotericin B + L-AmB standard dose | Gilead Sciences | Phase 3 | 76 |
| BAY 3389934 + Matching Placebo / Diluent | Bayer | Phase 1 | 30 |
| Flucytosine and fluconazole + Fluconazole | Bausch Health | Phase 2 | 47 |